Back to $120Absolutely nothing has changed here, other than that CXR has completed an outstanding and transformative acquisition.
The recent hubris in health care stocks was falsely generated by unscrupulous newsletter writers aided and abetted by the short and distort compaign.
Our financial metrics remain unchanged and this sector is still the best to be invested in.
For these reasons, I see no reason why CXR should not return to its former trading range above $100..